Boston Scientific has announced that it will make a €30 million investment in research, development and innovation (RD&I) at its Cork facility. The investment is being made with the aim of accelerating the firm’s development and manufacture of minimally invasive technologies for the treatment of cancer and peripheral arterial diseases.
The investment is being made with the support of IDA Ireland, the Irish government’s agency for attracting foreign direct investment (FDI) in Ireland. The funding will help to diversify the technologies developed and manufactured at the Cork facility and is forecast to support the creation of over 70 new jobs over the next three years.
Currently, the company’s Cork site employs over 1,200 staff and produces devices for a range of treatments, including digestive disorders, interventional oncology, severe asthma and coronary artery disease.
Boston Scientific’s Vice-President Operations in Cork, Sean Gayer, said: “Boston Scientific first established its Irish footprint in 1994 and today is the largest life sciences employer in Ireland. With a workforce of more than 6,000 people across three locations at Galway, Clonmel and Cork, the company exports more than 12 million medical devices annually.”
“We are delighted to be adding new quality, engineering and production capabilities to our Cork facility and contributing further to the strong medtech sector in the region. We appreciate the Irish Government support through IDA Ireland.”
IDA Ireland CEO Martin Shanahan commented that, as Boston Scientific expands in Cork, “its continued investment in ongoing operations and highly skilled local talent is encouraging.” He added that this “expansion is further evidence of the southwest region’s thriving medtech cluster.”